Pharmacological mechanisms of carvacrol against hepatocellular carcinoma by network pharmacology and molecular docking
Technology and Health Care · 2025-07 · 33 (4) · 1850-1867
DOI: 10.1177/09287329241306192 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology and Health Care, online erschienen am 04.02.2025. Verfasst von Lu Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Zhejiang University, Lishui Hospital, Lishui City, Zhejiang Province, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Cymenes, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Background
Preclinical studies have demonstrated that carvacrol possesses various biological and pharmacological properties, including anti-hepatocellular carcinoma (HCC) effects. However, the molecular basis of its therapeutic action on HCC remains unclear.
Objective
The aim of this study was to investigate and further validate the multi-target therapeutic mechanism of carvacrol against HCC.
Methods
The chemical structure of carvacrol was obtained from the PubChem database, and its potential targets were identified using SwissTargetPrediction, HERB, and BATMAN-TCM. HCC-specific genes were screened from the TCGA-LIHC cohort. The therapeutic targets of carvacrol against HCC were determined through the intersection of these datasets. Subsequently, a multivariate Cox regression prognostic model was established. Molecular docking was performed to analyze the interactions between carvacrol and its therapeutic targets. Additionally, molecular dynamics simulations were conducted to validate the molecular docking results using Discovery Studio 2019 software.
Results
A total of 223 carvacrol targets and 882 HCC-specific genes were identified. Fifteen therapeutic targets of carvacrol against HCC were obtained, including CA2, AR, ALB, AURKA, ALPL, EPHX2, BCHE, IL1RN, AGRN, CRP, DMGDH, APOA1, SOX9, HPX, and CHKA. The prognostic model accurately and independently predicted survival outcomes. AGRN and AURKA were significantly associated with HCC overall survival. Molecular docking and molecular dynamics simulations demonstrated that carvacrol exhibited strong potential for stable binding to the therapeutic targets AGRN and AURKA.
Conclusion
Our findings elucidate the multi-target mechanism of action of carvacrol against HCC, providing a foundation for future research on its application in HCC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, Zhejiang University, Lishui Hospital, Lishui City, Zhejiang Province, China.
- Cancer Center, The Fifth Affiliated Hospital of Wenzhou Medical College, Lishui City, Zhejiang Province, China.
- Cancer Center, Lishui Central Hospital, Lishui City, Zhejiang Province, China.
- Department of Pharmacy, Shaoxing People's Hospital, Shaoxing City, Zhejiang Province, China.
- Department of Pharmacy, Shaoxing Hospital Affiliated Zhejiang University School of Medicine, Shaoxing City, Zhejiang Province, China.
- Department of Radiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou City, Zhejiang, China.
Zitieren
APA
Liu, L., Yu, P., Zhao, Z., Yang, H., & Yu, R. (2025). Pharmacological mechanisms of carvacrol against hepatocellular carcinoma by network pharmacology and molecular docking. Technology and Health Care, 33(4), 1850-1867. https://doi.org/10.1177/09287329241306192
Vancouver
Liu L, Yu P, Zhao Z, Yang H, Yu R. Pharmacological mechanisms of carvacrol against hepatocellular carcinoma by network pharmacology and molecular docking. Technology and Health Care. 2025;33(4):1850-1867. doi:10.1177/09287329241306192
BibTeX
@article{Liu2025,
author = {Liu, Lu and Yu, Ping and Zhao, Zhongwei and Yang, Hongyuan and Yu, Risheng},
title = {Pharmacological mechanisms of carvacrol against hepatocellular carcinoma by network pharmacology and molecular docking},
journal = {Technology and Health Care},
year = {2025},
volume = {33},
number = {4},
pages = {1850--1867},
doi = {10.1177/09287329241306192}
}
EUVIMED